Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands

Current Medical Research and Opinion

Volumn 24, Issue 3, 2008, Pages 671-684

  Jansen, Jeroen P ^a   Gaugris, Sabine ^b   Bergman, Gert ^a   Sen, Shuvayu S ^b  

^a MAPI GROUP   (Netherlands)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alendronate; Bone fractures; Cholecalciferol; Cost effectiveness; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID PLUS COLECALCIFEROL; COLECALCIFEROL; IBANDRONIC ACID;

ARTICLE; CAUSE OF DEATH; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH STATUS; HIP FRACTURE; HUMERUS FRACTURE; NETHERLANDS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SIMULATION; UNITED KINGDOM; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION; WRIST FRACTURE;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; CHOLECALCIFEROL; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; DRUG COMBINATIONS; DRUG COSTS; FEMALE; FRACTURES, BONE; GREAT BRITAIN; HUMANS; MIDDLE AGED; MODELS, ECONOMIC; NETHERLANDS; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT SIMULATION; QUALITY-ADJUSTED LIFE YEARS;

EID: 41149179144     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X260998     Document Type: Article

References (53)

1. Deal CL. Osteoporosis: prevention, diagnosis, and management. Am J Med 1997;102:35S-9
2. The burden of musculoskeletal conditions at the start of the new millennium: a report of a WHO scientific group. WHO Technical Report Series 919, World Health Organization, Geneva 2003. Health Technol Assess 2004;8:1-78
3. Melton LJ, 3rd. Hip fractures: a worldwide problem today and tomorrow. Bone, 1993;14(Suppl 1):S1-8
4. Klift M van der, Laet CEDH de, McCloskey EV, et al. The incidence of vertebral fractures in men and women: The Rotterdam Study. J Bone Miner Res 2002;17:1051-6
5. Kanis JA, Pitt FA. Epidemiology of osteoporosis. Bone 1992;13(Suppl 1):S7-15
6. Dolan P, Torgerson DJ. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 1998;8:611-7
7. SIGN (2003) Management of osteoporosis. Scottish Intercollegiate Guidelines Network. Available from http://www.sign.ac.uk [Last accessed 6 June 2007]
8. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
9. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118-24
10. Montero-Odasso M, Duque G. Vitamin D in the aging musculoskeletal system: an authentic strength preserving hormone. Mol Aspects Med 2005;26:203-19
11. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004;291:1999-2006
12. Bischoff-Ferrari HA, Conzelmann M, Stahelin HB, et al. Is fall prevention by vitamin D mediated by a change in postural or dynamic balance? Osteoporos Int 2006;17:656-63
13. Staud R. Vitamin D: more than just affecting calcium and bone. Curr Rheumatol Rep 2005;7:356-64
14. Blake AJ, Morgan K, Bendall MJ, et al. Falls by elderly people at home: prevalence and associated factors. Age Ageing 1988;17:365-72
15. Cummings SR, Nevitt MC. Falls. N Engl J Med 1994;331:872-3
16. Drinka PJ. The importance of parathyroid hormone and vitamin D status in the treatment of osteoporosis and renal insufficiency. J Am Med Dir Assoc 2006;7:S5-9
17. Forli L, Halse J, Haug E, et al. Vitamin D deficiency, bone mineral density and weight in patients with advanced pulmonary disease. J Intern Med 2004;256:56-62
18. Heaney RP. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr 2004;80:1706S-9
19. Lips P. Vitamin D physiology. Prog Biophys Mol Biol 2006;92:4-8
20. Pasco JA, Henry MJ, Kotowicz MA, et al. Seasonal periodicity of serum vitamin D and parathyroid hormone, bone resorption, and fractures: the Geelong Osteoporosis Study. J Bone Miner Res 2004;19:752-8
21. Osteoporosis Society of Canada. Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada. CMAJ 1996;155:1113-33
22. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
23. Malavolta N, Pratelli L, Frigato M, et al. The relationship of vitamin D status to bone mineral density in an Italian population of postmenopausal women. Osteoporos Int 2005;16:1691-7
24. von Mühlen DG, Greendale GA, Garland CF, et al. Vitamin D, parathyroid hormone levels and bone mineral density in community-dwelling older women: the Rancho Bernardo Study. Osteoporos Int 2005;16:1721-6
25. Koster JC, Hackeng WH, Mulder H. Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women. Eur J Clin Pharmacol 1996;51:145-7
26. Stevenson M, Jones ML, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1-160
27. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
28. Kanis JA, Brazier JE, Stevenson M, et al. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2002;6:1-146
29. Slobbe LCJ, Kommer GJ, Smit JM Kosten van ziekten in Nederland 2003. Zorg voor euro's [Costs of illness in the Netherlands 2003] Rijksinstituut voor Volksgezondheid en Milieu, RIVM; 2006
30. Osteoporose Tweede herziene richtlijn 2002. English summary published in Pols HA, Wittenberg J. CBO guideline "Osteoporosis" (second version). NTVG Ned Tijdschr Geneeskd 2002;146:1359-63.
31. Centraal Bureau voor de Statistiek [Central Office for Statistics]. Statline database, 2004. Available from http://www.cbs.nl [Last accessed 27 July 2007]
32. Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15 721-39
33. Government Actuary Department, 1999. Available from http://www.gad.gov.uk [Last accessed 14 July 2005]
34. Oden A, Dawson A, Dere W, et al. Lifetime risk of hip fractures is underestimated. Osteoporos Int 1998;8:599-603
35. Meyer HE, Tverdal A, Falch JA, Pedersen JI. Factors associated widi mortality after hip fracture. Osteoporos Int 2000;11 228-32
36. Poor G, Atkinson EJ, O'Fallon WM, Melton III. Determinants of reduced survival following hip fractures in men. Clin Orthop Relat Res 1995;319:260-5
37. Todd CJ, Freeman C, Camilleri-Ferrante C, Laxton C, Muriel P, Palmer C et al. Anglian audit of hip fracture 2. Cambridge: Cambridge Health Services Research Group, University of Cambridge; 1999.
38. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey [comment]. BMJ 1998;316 736-41
39. British National Formulary. Available from http://www.bnf.org/bnf/bnf/ current/openat/index.htm [Last accessed 30 June 2005]
40. CvZ. (College voor Zorgverzekering) [Health Care Insurance Board]. Z-index. Available from http://www.medicijnkosten.nl [Last accessed 30 June 2005]
41. Curtis L, Netten A (Personal Social Services Research Unit). Unit costs of health and social care 2004. Available from http://www.pssru.ac.uk [14 July 2005]
42. Oostenbrink JB, Koopmanschap MA, Rutten FF. Manual for cost calculations: methods and recommended prices for economic evaluations in health care. Handleiding voor kostenberekeningen: methoden en richtlijnprijzen voor economische evaluaties in de gezondheidszorg. Amstelveen: College voor zorgverzekeringen, 2004
43. Kanis JA, Jonsson B. Economic evaluation of interventions for osteoporosis. Osteoporos Int 2002;13:765-7
44. Stevenson MD, Oakley J, Chilcott JB. Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis. Med Decis Making 2004;24:89-100
45. Tappenden P, Chilcott JB, Eggington S, et al. Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis. Health Technol Assess 2004;8:iii,1-78
46. Holick MF, Siris ES, Binkley N, et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005;90:3215-24
47. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22
48. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2007 [Epub ahead of print 13 Nov 2007]
49. Adachi J, Lynch N, Middelhoven H, et al. The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMC Musculoskelet Disord 2007;8:97 [Epub ahead of print 26 Sept 2007]
50. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60
51. Cramer JA, Lynch NO, Gaudin AF, et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 2006;28:1686-94
52. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18:1023-31
53. Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 2006;22:2383-91